We are live on ! Find out more
PACB icon

Pacific Biosciences
PACB

101 hedge funds and large institutions have $342M invested in Pacific Biosciences in 2014 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 31 increasing their positions, 27 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

150% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 10

113% more call options, than puts

Call options by funds: $540K | Put options by funds: $253K

93% more capital invested

Capital invested by funds: $178M → $342M (+$164M)

15% more repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 27

15% more funds holding

Funds holding: 88 → 101 (+13)

Holders
101
Holders Change
+13
Holders Change %
+14.77%
% of All Funds
2.69%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.03%
New
25
Increased
31
Reduced
27
Closed
10
Calls
$540K
Puts
$253K
Net Calls
+$287K
Net Calls Change
+$209K

Top Buyers

1
DM
Deerfield Management
New York
+$4.62M
2
BG
BlackRock Group
United Kingdom
+$4.13M
3
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$3.16M
4
Millennium Management
Millennium Management
New York
+$1.82M
5
IG
ING Group
Netherlands
+$1.6M

Top Sellers

1
RCM
Raging Capital Management
New Jersey
-$7.75M
2
Goldman Sachs
Goldman Sachs
New York
-$2.16M
3
BIM
Bogle Investment Management
Massachusetts
-$1.01M
4
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
-$646K
5
PPA
Parametric Portfolio Associates
Washington
-$640K
Name Holding Trade Value Shares
Change 		Change in
Stake
RG
26
Redmile Group
California
$1.87M +$1.52M +237,977 New
Connor, Clark & Lunn Investment Management (CC&L)
27
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$1.79M +$6.4K +1,000 +0.4%
TCIM
28
TIAA CREF Investment Management
New York
$1.63M -$196K -30,640 -13%
Invesco
29
Invesco
Georgia
$1.47M +$1.2M +186,862 New
Deutsche Bank
30
Deutsche Bank
Germany
$1.28M +$47K +7,353 +5%
EIM
31
Essex Investment Management
Massachusetts
$1.19M -$153K -23,949 -14%
NI
32
Numeric Investors
Massachusetts
$1.17M +$953K +149,000 New
AQR Capital Management
33
AQR Capital Management
Connecticut
$1.15M -$37.4K -5,840 -4%
Renaissance Technologies
34
Renaissance Technologies
New York
$1.08M +$883K +137,972 New
CS
35
Credit Suisse
Switzerland
$1.04M +$549K +85,737 +183%
PPA
36
Parametric Portfolio Associates
Washington
$1.01M -$640K -100,014 -44%
WMSA
37
Weiss Multi-Strategy Advisers
New York
$841K – – –
California State Teachers Retirement System (CalSTRS)
38
California State Teachers Retirement System (CalSTRS)
California
$836K +$2.9K +454 +0.4%
AllianceBernstein
39
AllianceBernstein
Tennessee
$757K +$125K +19,600 +25%
CLOS
40
Compagnie Lombard Odier SCmA
Switzerland
$721K -$335K -52,341 -36%
Charles Schwab
41
Charles Schwab
California
$672K – – –
TA
42
Teachers Advisors
New York
$655K – – –
NFA
43
Nationwide Fund Advisors
Ohio
$629K +$20.1K +3,149 +4%
ARTA
44
A.R.T. Advisors
New York
$619K +$506K +79,056 New
Jacobs Levy Equity Management
45
Jacobs Levy Equity Management
New Jersey
$582K -$230K -36,000 -33%
Two Sigma Advisers
46
Two Sigma Advisers
New York
$569K +$465K +72,600 New
RhumbLine Advisers
47
RhumbLine Advisers
Massachusetts
$518K +$74.3K +11,605 +21%
Two Sigma Investments
48
Two Sigma Investments
New York
$498K +$406K +63,466 New
Fidelity Investments
49
Fidelity Investments
Massachusetts
$470K +$384K +60,000 New
ProShare Advisors
50
ProShare Advisors
Maryland
$467K +$2.37K +371 +0.6%
1
2
3 4 5

PACB Hedge Fund Activity: Q4 2014 in Review

101 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Pacific Biosciences (PACB) for Q4 2014, worth a combined $342M — up 93% from $178M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new PACB positions and 10 closed out — a net gain of 15 holders — while 31 added to existing stakes and 27 trimmed.

The largest buyer was Deerfield Management, adding an estimated $4.62M. The largest seller was Raging Capital Management, exiting entirely with an estimated $7.75M sold.

  • 101 institutional investors held Pacific Biosciences (PACB) as of Q4 2014, up from 88 in Q3 2014.
  • Funds reported $342M of Pacific Biosciences stock for Q4 2014, up 93% quarter-over-quarter.
  • 25 funds opened new Pacific Biosciences positions in Q4 2014 and 10 closed out, a net change of +15 holders.
  • The largest Pacific Biosciences buyer in Q4 2014 was Deerfield Management, an estimated $4.62M added.
  • The largest Pacific Biosciences seller in Q4 2014 was Raging Capital Management, an estimated $7.75M sold.

Based on aggregated 13F filings for Q4 2014.